The Cardiorenal Syndrome: Pathophysiologic Crosstalk, Outcomes, and Treatment Targets

ISSN: 2212-4063 (Online)
ISSN: 1871-529X (Print)


Volume 14, 3 Issues, 2014


Download PDF Flyer




Cardiovascular & Hematological Disorders-Drug Targets

Formerly: Current Drug Targets - Cardiovascular & Hematological Disorders

Aims & ScopeAbstracted/Indexed in


Submit Abstracts Online Submit Manuscripts Online

Editor-in-Chief:
Garry X. Shen
University of Manitoba
Winnipeg, MB
Canada


View Full Editorial Board

Subscribe Purchase Articles Order Reprints


The Cardiorenal Syndrome: Pathophysiologic Crosstalk, Outcomes, and Treatment Targets

Author(s): L Cohen

Affiliation: Duke University School of Medicine, P.O. Box 100800, Durham, NC 27705, USA

Abstract

The development of simultaneous decompensation in cardiac and renal function is a common phenomenon in patients with congestive heart failure. Termed the cardiorenal syndrome (CRS), this joint deterioration in cardiac output and renal filtration is the result of a complex interplay of hemodynamic and neurohormonal factors. Recently, endothelial dysfunction, inflammation and uremia have been recognized as contributors to the crosstalk responsible for the development of CRS. Management strategies for the treatment of CRS involve correction of hemodynamic derangements and regulation of neurohormonal pathways. Future therapies may target more newly recognized components of CRS pathophysiologic development

Keywords: Cardiorenal syndrome, heart failure, kidney injury, renal failure, venous congestion, volume overload

Purchase Online Rights and Permissions

  
  



Article Details

Volume: 14
First Page: 1
Last Page: 7
Page Count: 7
DOI: 10.2174/1871529X14666140701100913
Advertisement

Related Journals




Webmaster Contact: urooj@benthamscience.org Copyright © 2014 Bentham Science